Author

Sarah Abou Alaiwi

Dana-Farber Cancer InstituteORCID 0000-0002-7073-3432Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Genetic & Genomic Medicine· 1 Genomics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Approach:statistical model· 2 Research Focus:benchmarking· 1 Research Focus:cancer & tumor microenvironment· 1 Assay:ChIP-seq· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

Matthew L. FreedmaniD· 3 shared Amin H. NassariD· 2 shared Chris LabakiiD· 2 shared David A. BrauniD· 2 shared Eliezer M. Van AlleniD· 2 shared Ji-Heui SeoiD· 2 shared Justin H. HwangiD· 2 shared Sylvan C. BacaiD· 2 shared

Activity by Year

2022-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersGenomics

Matthew L. FreedmanORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

GenomicsCell ReportsPeer-reviewedJun 1, 2024

Epigenomic signatures as circulating and predictive biomarkers in sarcomatoid renal cell carcinoma

Talal El Zarif, Karl Semaan, Marc Eid…·Sylvan C. Baca

The paper identifies epigenomic signatures in sarcomatoid renal cell carcinoma (sRCC) that predict response to immune checkpoint inhibitors and are detectable in plasma, enabling non-invasive diagnosis.

30 citationstop 2%

humanDNA methylation

𝕏 PostBluesky

Genetic & Genomic MedicinemedRxivPreprintApr 10, 2022

Germline variants associated with immunotherapy-related adverse events

Stefan Groha, Sarah Abou Alaiwi, Wenxin Vincent Xu…·Alexander Gusev

This study identifies three germline variants associated with immune-related adverse events in patients treated with immune checkpoint inhibitors.

DOI 10.1101/2022.04.10.22273627

humanGWAS summary statistics

𝕏 PostBluesky

Cancer BiologyCell ReportsPeer-reviewedFeb 1, 2022

A genome-scale CRISPR screen reveals PRMT1 as a critical regulator of androgen receptor signaling in prostate cancer

Stephen Tang, Nebiyou Y. Metaferia, Marina F. Nogueira…·Srinivas R. Viswanathan

This study identifies PRMT1 as a critical regulator of AR signaling in prostate cancer through genome-scale CRISPR screening and shows its potential as a therapeutic target.

DOI 10.1016/j.celrep.2022.110417

humangenetic perturbation / CRISPR

𝕏 PostBluesky